Routine Assays Logo
Routine Assays Logo

Routine Assays

3rd Party Haemostasis Reagents

Achieve cost-efficiencies and replace any problematic assays with third party haemostasis reagents.

A comprehensive range of reagents for diagnostic testing of disease and blood disorders, relating to Coagulation, Haemophilia, Thrombophilia, Fibrinolysis and Platelet Function.

Our reagents are manufactured by Helena Biosciences who specialise in the supply of 3rd party haemostasis reagents for use on the majority of the coagulation instruments currently in use in the UK and Ireland.  With all 3rd party reagents application notes will be provided specific to the instrument in your laboratory.  This offers the opportunity to achieve cost-efficiencies and potential to replace any underperforming or problematic assays.

Thromboplastin LI
Thromboplastin LI

Thromboplastin LI is of rabbit brain origin and used for the determination of Prothrombin Time, investigation of the extrinsic pathway and monitoring of oral anticoagulant therapy in citrated human plasma.

Thromboplastin L
Thromboplastin L

Thromboplastin L is calcified Rabbit Brain Thromboplastin Suspension used for the determination of Prothrombin Time, investigation of the extrinsic pathway and monitoring of oral anticoagulant therapy in citrated human plasma

Capillary Thromboplastin
Capillary Thromboplastin

Capillary Thromboplastin is of rabbit brain origin and used for the determination of Prothrombin Time, investigation of the extrinsic pathway and monitoring of oral anticoagulant therapy in capillary blood and citrated human plasma.

APTT Si L Minus from Helena Biosciences
APTT Si L Minus

APTT Si L Minus contains phospholipid extract and a near-colloidal particle activator. It is for use in the determination of Activated Partial Thromboplastin Times (aPTT), related coagulation factor assays, pre-surgical screening and monitoring of Heparin therapy using citrated plasma. The reagent can be used on manual, semi-automated and automated methods.

APTT Si L Plus
APTT Si L Plus

APTT Si L Plus contains phospholipid extract and a near-colloidal particle activator. It is for use in the determination of Activated Partial Thromboplastin Times (aPTT) with sensitivity to lupus-like inhibitors, related coagulation factor assays, pre-surgical screening and monitoring of Heparin therapy using citrated plasma. The reagent can be used on manual, semiautomated and automated methods.

APTT SA from Helena Biosciences
APTT SA

APTT SA contains dehydrated rabbit brain extract with ellagic acid as a soluble activator. It is for use in the determination of activated partial thromboplastin times (aPTT) and related coagulation procedures using manual, semi-automated and automated methods and in the monitoring of Heparin therapy.

0.025M Calcium Chloride for use in conjunction with Helena Biosciences Thromboplastin and APTT reagents.
Calcium Chloride

0.025M Calcium Chloride for use in conjunction with Helena Biosciences Thromboplastin and APTT reagents.

Clauss Fibrinogen 35 is intended for the quantitative determination of Fibrinogen based on the Clauss method, in human citrated plasma on IL/ACL Coagulation Systems. Thrombin is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the fibrinogen concentration.
Clauss Fibrinogen 35

Clauss Fibrinogen 35 is intended for the quantitative determination of Fibrinogen based on the Clauss method, in human citrated plasma on IL/ACL Coagulation Systems. Thrombin is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the fibrinogen concentration.

Clauss Fibrinogen 50 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Owren’s Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.
Clauss Fibrinogen 50

Clauss Fibrinogen 50 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Owren’s Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Clauss Fibrinogen 50 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Imidazole Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.
Clauss Fibrinogen 50

Clauss Fibrinogen 50 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Imidazole Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Clauss Fibrinogen 100 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Owren’s Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.
Clauss Fibrinogen 100

Clauss Fibrinogen 100 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Owren’s Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Clauss Fibrinogen 100 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Imidazole Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.
Clauss Fibrinogen 100

Clauss Fibrinogen 100 is intended for the quantitative determination of Fibrinogen in citrated human plasma, utilising Imidazole Buffer. An excess of Thrombin (>30 NIH units/mL) is added to human plasma to convert Fibrinogen to Fibrin, the clot time is directly proportional to the Fibrinogen concentration.

Clauss Fibrinogen (Thrombin only) is intended for use in the quantitative determination of Fibrinogen in human plasma using the Clauss Method.
Clauss Fibrinogen (Thrombin only)

Clauss Fibrinogen (Thrombin only) is intended for use in the quantitative determination of Fibrinogen in human plasma using the Clauss Method.

Imidazole can be used with Clauss Fibrinogen and Factor assays to dilute standards, control plasma and patient plasma for manual, semi-automated and fully automated methods.
Imidazole Buffer

Imidazole can be used with Clauss Fibrinogen and Factor assays to dilute standards, control plasma and patient plasma for manual, semi-automated and fully automated methods.

Owren’s Buffer can be used with Clauss Fibrinogen and Factor assays to dilute standards, control plasma and patient plasma for manual, semi-automated and fully automated methods.
Owren's Buffer

Owren’s Buffer can be used with Clauss Fibrinogen and Factor assays to dilute standards, control plasma and patient plasma for manual, semi-automated and fully automated methods.

Kaolin Suspension is used to reconstitute Thrombin where instrument methodology indicates Kaolin reconstitution of the Thrombin reagent is required for use in Clauss Fibrinogen assays.
Kaolin Suspension

Kaolin Suspension is used to reconstitute Thrombin where instrument methodology indicates Kaolin reconstitution of the Thrombin reagent is required for use in Clauss Fibrinogen assays.

The Thrombin Time reagent is intended to give a qualitative indication of abnormal Fibrinogen levels, or the presence of interfering substances such as FDPs or Heparin. Quantitative evaluation of the possible causes of prolonged Thrombin Times should be performed as follow-up studies.
Thrombin Time

The Thrombin Time reagent is intended to give a qualitative indication of abnormal Fibrinogen levels, or the presence of interfering substances such as FDPs or Heparin. Quantitative evaluation of the possible causes of prolonged Thrombin Times should be performed as follow-up studies.